Lyell Immunopharma (LYEL)
(Real Time Quote from BATS)
$1.45 USD
-0.04 (-2.69%)
Updated Aug 5, 2024 10:00 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LYEL 1.45 -0.04(-2.69%)
Will LYEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LYEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LYEL
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
LYEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Other News for LYEL
What You Missed On Wall Street This Morning
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls
Lyell Immunopharma price target lowered by $3 at BofA, here's why
Hold Rating on Lyell Immunopharma Amid Safety Concerns and Efficacy Doubts for LYL797 Treatment
Lyell Immunopharma just downgraded at H.C. Wainwright, here's why